The rise in IGF-1 levels after leptin therapy was found to correspond with improvements in NAS, NASH score, and hepatic fat content, suggesting IGF-1's potential as a biomarker for monitoring the effectiveness of leptin replacement therapy in individuals with PL. This evidence concerns the gene IGF1 and neonatal abstinence syndrome.